Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals
- 9 January 2019
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 68 (5) , 906-917
Abstract
The incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are secreted postprandially and contribute importantly to postprandial glucose tolerance. Here, we assessed the individual and combined contributions of endogenous GIP and GLP-1 to the postprandial changes in glucose and gluco-regulatory hormones using the novel GIP receptor antagonist GIP(3-30)NH2 and the well-established GLP-1 receptor antagonist exendin(9-39)NH2. During four-hour oral glucose tolerance tests (75 g) combined with an ad libitum meal test, 18 healthy men received on four separate days in randomized, double-blinded order intravenous infusions of A) GIP(3-30)NH2 (800 pmol/kg/min)+exendin(9-39)NH2 (0-20 min: 1,000 pmol/kg/min; 20-240 min: 450 pmol/kg/min), B) GIP(3-30)NH2, C) exendin(9-39)NH2, and D) saline, respectively. Glucose excursions were significantly higher during A than during B, C, and D while glucose excursions during B were higher than during C and D. Insulin secretion (assessed by C-peptide:glucose ratio) was reduced by 37±16% (A), 30±17% (B), and 8.6±16% (C) compared to D (mean±standard deviation). A and C resulted in higher glucagon levels, and faster gastric emptying. In conclusion, endogenous GIP affects postprandial plasma glucose excursions and insulin secretion more than endogenous GLP-1, but the hormones contribute additively to postprandial glucose regulation in healthy individuals. Trial no. (Clinicaltrials.gov): NCT03133741Keywords
Funding Information
- European Foundation for the Study of Diabetes
This publication has 50 references indexed in Scilit:
- Glucose-Dependent Insulinotropic PolypeptideDiabetes, 2011
- Gastric Bypass Surgery Enhances Glucagon-Like Peptide 1–Stimulated Postprandial Insulin Secretion in HumansDiabetes, 2011
- Glucose-Dependent Insulinotropic Polypeptide May Enhance Fatty Acid Re-esterification in Subcutaneous Abdominal Adipose Tissue in Lean HumansDiabetes, 2010
- On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humansAmerican Journal of Physiology-Endocrinology and Metabolism, 2010
- Effects of peripheral administration of synthetic human glucose‐dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetesClinical Endocrinology, 2009
- Inhibition of Food Intake in Obese Subjects by Peptide YY3–36New England Journal of Medicine, 2003
- Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in manDigestive Diseases and Sciences, 1993
- GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MANThe Lancet, 1987
- The incretin concept todayDiabetologia, 1979
- Vagal, Cholinergic Regulation of Pancreatic Polypeptide SecretionJournal of Clinical Investigation, 1978